Karyn S. Eilber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karyn S. Eilber has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Tash Anger
Department of Urology, University of California San Diego Health, San Diego, USA
10 shared publications - Anne Lenore Ackerman
Affiliation Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America
4 shared publications - Claire S. Burton
Fellow, University of California Los Angeles, Department of Urology, Los Angeles, CA, USA
2 shared publications - Deven C. Patel
Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA
2 shared publications - Kai B. Dallas
Stanford University School of Medicine, Stanford, CA
2 shared publications Lauren N. Wood
Division of Urology, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California
2 shared publications
Latest Publications
- Open Access
- 19 December 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (7) , 3602-3605
Prevalence of radiographic misinterpretation of urethral bulking agents: a retrospective, single-center study
Purpose: Urethral bulking agents (UBA) are a treatment option for patients with stress urinary incontinence and can contain radiopaque material such that misdiagnosis for pelvic pathology occurs. We aim to characterize radiologic interpretation of UBA in patients who had computed tomography of the abdomen and pelvis (CTAP) after UBA. Methods: All patients who underwent UBA from January 2011 to March 2024 were identified in the electronic medical record (EMR). Charts were reviewed to identify patients who underwent subsequent CTAP. Radiologic interpretations were reviewed to assess for accuracy in identification of the UBA as well as patient communications regarding imaging results. Results: During the study period, 144 patients underwent injection of UBA. Of those, 31 patients had ≥ 1 CTAP for a total of 61 CTAPs. Average duration of UBA to CTAP was 25.7 months. The UBA was accurately identified in only 15 (24.6%) scans. In 31 (50.8%) scans, neither UBA nor any abnormality was noted, and one of the authors confirmed presence of UBA in 30 of the 31 scans. UBA was inaccurately characterized as bladder stones ( n = 7), nonspecific calcifications ( n = 6), radiodense material ( n = 1), and a urethral stone ( n = 1) in the remaining 15 (24.6%) scans. Two patients with UBA who were misdiagnosed as bladder stones messaged via the patient portal about the findings with one expressing anxiety regarding the finding. Conclusions: Urethral bulking agents are often inaccurately interpreted on CTAP potentially leading to anxiety and unnecessary intervention. This highlights the importance of raising awareness of UBA among radiologists.
- 19 December 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (7) , 3602-3605
Open AccessPrevalence of radiographic misinterpretation of urethral bulking agents: a retrospective, single-center study
Purpose: Urethral bulking agents (UBA) are a treatment option for patients with stress urinary incontinence and can contain radiopaque material such that misdiagnosis for pelvic pathology occurs. We aim to characterize radiologic interpretation of UBA in patients who had computed tomography of the abdomen and pelvis (CTAP) after UBA. Methods: All patients who underwent UBA from January 2011 to March 2024 were identified in the electronic medical record (EMR). Charts were reviewed to identify patients who underwent subsequent CTAP. Radiologic interpretations were reviewed to assess for accuracy in identification of the UBA as well as patient communications regarding imaging results. Results: During the study period, 144 patients underwent injection of UBA. Of those, 31 patients had ≥ 1 CTAP for a total of 61 CTAPs. Average duration of UBA to CTAP was 25.7 months. The UBA was accurately identified in only 15 (24.6%) scans. In 31 (50.8%) scans, neither UBA nor any abnormality was noted, and one of the authors confirmed presence of UBA in 30 of the 31 scans. UBA was inaccurately characterized as bladder stones ( n = 7), nonspecific calcifications ( n = 6), radiodense material ( n = 1), and a urethral stone ( n = 1) in the remaining 15 (24.6%) scans. Two patients with UBA who were misdiagnosed as bladder stones messaged via the patient portal about the findings with one expressing anxiety regarding the finding. Conclusions: Urethral bulking agents are often inaccurately interpreted on CTAP potentially leading to anxiety and unnecessary intervention. This highlights the importance of raising awareness of UBA among radiologists.
- Open Access
Expert Opinions on Best Practices for Overactive Bladder Management with onabotulinumtoxinA
OnabotulinumtoxinA is an FDA-approved treatment for adults with overactive bladder (OAB) who have an inadequate response to, or are intolerant of, oral pharmacotherapies including anticholinergics or beta-3 agonists. However, procedural practices of onabotulinumtoxinA intradetrusor injection vary among practitioners and can affect patient experience. To address this, a panel of six high-volume intravesical onabotulinumtoxinA providers with 100 years of combined experience convened to discuss the best office practices when treating patients with OAB. These key best practices include counseling patients on available OAB therapies, including onabotulinumtoxinA, at the initial consultation in accordance with established AUA and SUFU guidelines in a way that is easily understood. An office setting is preferred over a hospital or surgery center when performing the procedure. Staff involvement, from scheduling to post-procedure, is essential for establishing the relationships necessary to optimize patient experience and encourage compliance and retreatment. Experts generally recommend using a viscous lidocaine bladder instillation for an anesthetic 15 min prior to the reconstitution of onabotulinumtoxinA with 5 to 10 mL of normal saline. A range of one to 20 injection sites is acceptable, with a smaller number preferred. Starting in the lower bladder, experts recommend using a slower speed of injection to improve distribution and decrease patient discomfort. Subsequent treatments should be regularly scheduled at six-month intervals with the option of re-treating earlier if symptoms return, but no sooner than 12 weeks. For office intravesical onabotulinumtoxinA procedures, optimization of the patient experience by the physician and their staff, starting with the initial visit through the post-treatment follow-up, is key to long-term patient compliance.
Open AccessExpert Opinions on Best Practices for Overactive Bladder Management with onabotulinumtoxinA
OnabotulinumtoxinA is an FDA-approved treatment for adults with overactive bladder (OAB) who have an inadequate response to, or are intolerant of, oral pharmacotherapies including anticholinergics or beta-3 agonists. However, procedural practices of onabotulinumtoxinA intradetrusor injection vary among practitioners and can affect patient experience. To address this, a panel of six high-volume intravesical onabotulinumtoxinA providers with 100 years of combined experience convened to discuss the best office practices when treating patients with OAB. These key best practices include counseling patients on available OAB therapies, including onabotulinumtoxinA, at the initial consultation in accordance with established AUA and SUFU guidelines in a way that is easily understood. An office setting is preferred over a hospital or surgery center when performing the procedure. Staff involvement, from scheduling to post-procedure, is essential for establishing the relationships necessary to optimize patient experience and encourage compliance and retreatment. Experts generally recommend using a viscous lidocaine bladder instillation for an anesthetic 15 min prior to the reconstitution of onabotulinumtoxinA with 5 to 10 mL of normal saline. A range of one to 20 injection sites is acceptable, with a smaller number preferred. Starting in the lower bladder, experts recommend using a slower speed of injection to improve distribution and decrease patient discomfort. Subsequent treatments should be regularly scheduled at six-month intervals with the option of re-treating earlier if symptoms return, but no sooner than 12 weeks. For office intravesical onabotulinumtoxinA procedures, optimization of the patient experience by the physician and their staff, starting with the initial visit through the post-treatment follow-up, is key to long-term patient compliance.
- Open Access
- 19 August 2023
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 18 (3) , 224-229
The Intersection of Female Sexual Function and Overactive Bladder
Purpose of Review: In this review, we discuss the available literature regarding the intersection of female sexual function and overactive bladder (OAB). Specifically, this review includes how OAB and its treatments affect female sexual function and quality of life. Recent Findings: Women suffering from overactive bladder have worse sexual function, and there are multiple prospective studies evaluating sexual function before and after overactive bladder treatment. Summary: There is a growing body of evidence demonstrating that traditional overactive bladder treatments not only improve OAB but can also improve sexual function.
- 19 August 2023
- Published by Springer Nature in Current Bladder Dysfunction Reports
- Vol. 18 (3) , 224-229
Open AccessThe Intersection of Female Sexual Function and Overactive Bladder
Purpose of Review: In this review, we discuss the available literature regarding the intersection of female sexual function and overactive bladder (OAB). Specifically, this review includes how OAB and its treatments affect female sexual function and quality of life. Recent Findings: Women suffering from overactive bladder have worse sexual function, and there are multiple prospective studies evaluating sexual function before and after overactive bladder treatment. Summary: There is a growing body of evidence demonstrating that traditional overactive bladder treatments not only improve OAB but can also improve sexual function.
- Open Access
- 1 July 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 34 (11) , 2713-2718
Can vaginal lactobacillus suppositories help reduce urinary tract infections?
Introduction and hypothesis: Recurrent urinary tract infections (rUTIs) are a burden to patients and the health care economy. Vaginal probiotics and supplements have gained significant attention in mainstream media and lay press as a non-antibiotic alternative. We performed a systematic review to determine whether vaginal probiotics are an effective means of prophylaxis for rUTI. Methods: A PubMed/MEDLINE article search was performed from inception to August 2022 for prospective, in vivo use of vaginal suppositories for the prevention of rUTIs. Search terms included: vaginal probiotic suppository (34 results), vaginal probiotic randomized (184 results), vaginal probiotic prevention (441 results), vaginal probiotic UTI (21 results), and vaginal probiotic urinary tract infection (91 results). A total of 771 article titles and abstracts were screened. Results: A total of 8 articles fit the inclusion criteria and were reviewed and summarized. Four were randomized controlled trials, with 3 of the studies having a placebo arm. Three were prospective cohort studies, and 1 was a single arm, open label trial. Five of the 7 articles that specifically evaluated for rUTI reduction with vaginal suppositories did find a decreased incidence with probiotic use; however, only 2 had statistically significant results. Both of these were studies of Lactobacillus crispatus and were not randomized. Three studies demonstrated the efficacy and safety of Lactobacillus as a vaginal suppository. Conclusion: Current data support the use of vaginal suppositories containing Lactobacillus as a safe, non-antibiotic measure, but actual reduction of rUTI in susceptible women remains inconclusive. The appropriate dosing and duration of therapy remain unknown.
- 1 July 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 34 (11) , 2713-2718
Open AccessCan vaginal lactobacillus suppositories help reduce urinary tract infections?
Introduction and hypothesis: Recurrent urinary tract infections (rUTIs) are a burden to patients and the health care economy. Vaginal probiotics and supplements have gained significant attention in mainstream media and lay press as a non-antibiotic alternative. We performed a systematic review to determine whether vaginal probiotics are an effective means of prophylaxis for rUTI. Methods: A PubMed/MEDLINE article search was performed from inception to August 2022 for prospective, in vivo use of vaginal suppositories for the prevention of rUTIs. Search terms included: vaginal probiotic suppository (34 results), vaginal probiotic randomized (184 results), vaginal probiotic prevention (441 results), vaginal probiotic UTI (21 results), and vaginal probiotic urinary tract infection (91 results). A total of 771 article titles and abstracts were screened. Results: A total of 8 articles fit the inclusion criteria and were reviewed and summarized. Four were randomized controlled trials, with 3 of the studies having a placebo arm. Three were prospective cohort studies, and 1 was a single arm, open label trial. Five of the 7 articles that specifically evaluated for rUTI reduction with vaginal suppositories did find a decreased incidence with probiotic use; however, only 2 had statistically significant results. Both of these were studies of Lactobacillus crispatus and were not randomized. Three studies demonstrated the efficacy and safety of Lactobacillus as a vaginal suppository. Conclusion: Current data support the use of vaginal suppositories containing Lactobacillus as a safe, non-antibiotic measure, but actual reduction of rUTI in susceptible women remains inconclusive. The appropriate dosing and duration of therapy remain unknown.
- Open Access
- 13 January 2023
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 11 (1) , 15-22
Is it time for doctors to Rx vibrators? A systematic review of pelvic floor outcomes
Vibrators and similar devices are an underutilized treatment modality in pelvic and sexual medicine, likely because of the limited knowledge on the health benefits of their use. The aim of this study was to review available data regarding the effect of vibrator use on sexual function, pelvic floor function, and chronic unexplained vulvar pain. We performed a systematic literature review of PubMed, Embase, and MEDLINE from inception to March 2021 per the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). The search was based on the following keywords: sex toy woman, pelvic vibrator, sexual stimulation vibrator, vaginal vibrator, vibrator pelvic floor, vibrator incontinence, and vulvar pain vibrator. An overall 586 articles were identified. Studies that met inclusion criteria were reviewed: original research, sample of women, vibrator use, and application to the pelvic/genital area. Exclusion criteria included case reports, unrelated content, vibrator not applied to the pelvic/genital area, male participants, or conditions of interest not addressed. A total of 17 original studies met the criteria and were reviewed in depth. After review of the literature and identification of articles appropriate for the study, there were 8 studies surrounding sexual function, 8 on pelvic floor function (muscle strength/urinary incontinence), and 1 on vulvar pain. Among the identified studies, vibrators were considered an accepted modality to enhance a woman’s sexual experience, improve pelvic floor muscle function, and facilitate treatment of vulvar pain. Vibrators are not well studied, and given the promising benefits demonstrated in the articles identified, future research efforts should be directed toward investigating their utility. Considering the potential pelvic health benefits of vibrators, their recommendation to women could be included in our pelvic floor disorder treatment armamentarium.
- 13 January 2023
- Published by Oxford University Press (OUP) in Sexual Medicine Reviews
- Vol. 11 (1) , 15-22
Open AccessIs it time for doctors to Rx vibrators? A systematic review of pelvic floor outcomes
Vibrators and similar devices are an underutilized treatment modality in pelvic and sexual medicine, likely because of the limited knowledge on the health benefits of their use. The aim of this study was to review available data regarding the effect of vibrator use on sexual function, pelvic floor function, and chronic unexplained vulvar pain. We performed a systematic literature review of PubMed, Embase, and MEDLINE from inception to March 2021 per the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses). The search was based on the following keywords: sex toy woman, pelvic vibrator, sexual stimulation vibrator, vaginal vibrator, vibrator pelvic floor, vibrator incontinence, and vulvar pain vibrator. An overall 586 articles were identified. Studies that met inclusion criteria were reviewed: original research, sample of women, vibrator use, and application to the pelvic/genital area. Exclusion criteria included case reports, unrelated content, vibrator not applied to the pelvic/genital area, male participants, or conditions of interest not addressed. A total of 17 original studies met the criteria and were reviewed in depth. After review of the literature and identification of articles appropriate for the study, there were 8 studies surrounding sexual function, 8 on pelvic floor function (muscle strength/urinary incontinence), and 1 on vulvar pain. Among the identified studies, vibrators were considered an accepted modality to enhance a woman’s sexual experience, improve pelvic floor muscle function, and facilitate treatment of vulvar pain. Vibrators are not well studied, and given the promising benefits demonstrated in the articles identified, future research efforts should be directed toward investigating their utility. Considering the potential pelvic health benefits of vibrators, their recommendation to women could be included in our pelvic floor disorder treatment armamentarium.
- 1 March 2019
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 11 (1) , 44-51
Female Cosmetic Genital Reconstruction: a Review of Current Trends, Treatments, and Techniques
- 1 March 2019
- Published by Springer Nature in Current Sexual Health Reports
- Vol. 11 (1) , 44-51
Female Cosmetic Genital Reconstruction: a Review of Current Trends, Treatments, and Techniques